Noida: Jubilant Pharmova Limited reported a solid financial performance for the quarter and half-year ended September 30, 2025, marking significant year-on-year growth in key financial metrics (Jubilant Pharmova Q2FY26).
Jubilant Pharmova Q2FY26 revenue stood at ₹1,966 crore, up 12% from the same quarter last year, with EBITDA growing 13% to ₹351 crore and normalized PAT increasing 21% to ₹124 crore.
Jubilant Pharmova Q2FY26: Broad-Based Growth Across Business Segments
The strong quarterly performance was driven by continued expansion in the company’s core verticals — Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and CRDMO.
Also Read: Pharma Exports Near USD 30 Billion as India Strengthens Biotech and MedTech Ecosystem
Revenue growth was primarily fueled by the start of revenue from the new and third production line at its Spokane, US facility, part of the CDMO Sterile Injectables business.
Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia noted that the company is on track to achieve its Vision 2030 objectives, emphasizing the positive impact of investments in Radiopharma and CRDMO. They added that growth momentum is expected to accelerate in the second half of FY26.
Jubilant Pharmova Q2FY26 and H1FY26 Financial Performance
For the first half of FY26, Jubilant Pharmova recorded revenue of ₹3,867 crore, an increase of 11% year-on-year, while EBITDA rose by 13% to ₹653 crore.
Normalized PAT for H1FY26 grew 32% to ₹227 crore, reflecting improved operating performance and lower finance costs.
Radiopharma and Allergy Immunotherapy Lead Segmental Gains
In Q2FY26, Radiopharmaceuticals revenue increased 16% to ₹291 crore, supported by strong uptake in Ruby-Fill® installations. Radiopharmacy revenues grew 7% to ₹607 crore, maintaining Jubilant’s position as the second-largest radiopharmacy network in the US.
The Allergy Immunotherapy business registered a 14% rise in revenue to ₹194 crore and a 65% jump in EBITDA, driven by higher demand from the US market.
Also Read: Akums Partners with Government of Zambia to Establish Pharmaceutical Manufacturing Facility
Jubilant Pharmova Q2FY26: CDMO and CRDMO Businesses Drive Future Growth
The CDMO Sterile Injectables business posted a 30% revenue increase to ₹393 crore, supported by the new production line at Spokane. EBITDA rose 6% to ₹94 crore. The next capacity expansion (Line 4) is expected to begin commercial operations by FY28.
The CRDMO business continued its growth trajectory, with the Drug Discovery vertical up 7% to ₹162 crore, and API revenue growing 8% to ₹137 crore. The company completed the sale of its API business to Jubilant Biosys Limited, integrating the API and CRDMO units for better operational efficiency.
Generics and Proprietary Novel Drugs Maintain Progress
The Generics division reported revenue of ₹167 crore, while the company plans to launch 6–8 new products annually in US and global markets. Meanwhile, clinical trials for lead proprietary drugs JBI-802 and JBI-778 are progressing as scheduled.
